Purple Biotech (PPBT) — Cash Flow-to-Debt Ratio
Purple Biotech (PPBT) has a Cash Flow-to-Debt Ratio of -1.28x as of June 2026, meaning its operating cash flow of $-2.50 Million could theoretically repay -1% of its total liabilities ($1.95 Million) in one year. See financial flexibility index of Purple Biotech to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Purple Biotech Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Purple Biotech across 13 annual periods. For the full cash flow conversion analysis, see how efficiently does Purple Biotech generate cash.
Annual Cash Flow-to-Debt Ratio for Purple Biotech (2013–2025)
Year-by-year debt coverage analysis for Purple Biotech. Check PPBT operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.70x | $-5.54 Million | $7.91 Million | ▲ +79.9% |
| 2024 | -3.48x | $-14.37 Million | $4.13 Million | ▼ -74.8% |
| 2023 | -1.99x | $-19.93 Million | $10.01 Million | ▲ +10.5% |
| 2022 | -2.22x | $-16.73 Million | $7.52 Million | ▲ +25.7% |
| 2021 | -3.00x | $-15.25 Million | $5.09 Million | ▼ -0.3% |
| 2020 | -2.98x | $-12.09 Million | $4.05 Million | ▼ -106.3% |
| 2019 | -1.45x | $-5.58 Million | $3.86 Million | ▲ +36.5% |
| 2018 | -2.28x | $-8.48 Million | $3.72 Million | ▼ -47.7% |
| 2017 | -1.54x | $-8.63 Million | $5.59 Million | ▲ +62.3% |
| 2016 | -4.10x | $-6.26 Million | $1.53 Million | ▼ -71.2% |
| 2015 | -2.39x | $-3.31 Million | $1.38 Million | ▲ +47.9% |
| 2014 | -4.59x | $-4.53 Million | $986.00K | ▼ -1026.9% |
| 2013 | -0.41x | $-512.00K | $1.26 Million | — |